142 related articles for article (PubMed ID: 18577438)
1. Ethyl docosahexaenoate decreased Neoral absorption due to particle size enlargement.
Hirunpanich V; Sugiyama E; Sato H
Int J Pharm; 2008 Sep; 361(1-2):251-2. PubMed ID: 18577438
[TBL] [Abstract][Full Text] [Related]
2. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient.
Hirunpanich V; Sato H
Eur J Pharm Biopharm; 2009 Oct; 73(2):247-52. PubMed ID: 19560537
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats.
Hirunpanich V; Katagi J; Sethabouppha B; Sato H
Drug Metab Dispos; 2006 Feb; 34(2):305-10. PubMed ID: 16299163
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
Hirunpanich V; Murakoso K; Sato H
Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
[TBL] [Abstract][Full Text] [Related]
5. Docosahexaenoic acid (DHA) inhibits saquinavir metabolism in-vitro and enhances its bioavailability in rats.
Hirunpanich V; Sato H
J Pharm Pharmacol; 2006 May; 58(5):651-8. PubMed ID: 16640834
[TBL] [Abstract][Full Text] [Related]
6. [The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats].
Liu XL; Tang J; Song J; He J; Xu P; Peng WX
Yao Xue Xue Bao; 2006 Sep; 41(9):882-7. PubMed ID: 17111838
[TBL] [Abstract][Full Text] [Related]
7. [Relative bioavailability of cyclosporine A-loaded hydroxypropyl methylcellulose phthalate nanoparticles for oral administration in rats].
Wang XQ; Dai JD; Zhang Q; Zhang T; Xia GM
Yao Xue Xue Bao; 2004 Jun; 39(6):463-6. PubMed ID: 15491107
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration.
Wang XQ; Dai JD; Chen Z; Zhang T; Xia GM; Nagai T; Zhang Q
J Control Release; 2004 Jul; 97(3):421-9. PubMed ID: 15212874
[TBL] [Abstract][Full Text] [Related]
9. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results.
Gan L; Gan Y; Zhu C; Zhang X; Zhu J
Int J Pharm; 2009 Jan; 365(1-2):143-9. PubMed ID: 18773948
[TBL] [Abstract][Full Text] [Related]
10. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A.
Song KH; Fasano A; Eddington ND
Int J Pharm; 2008 Mar; 351(1-2):8-14. PubMed ID: 17954018
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.
Onoue S; Sato H; Kawabata Y; Mizumoto T; Hashimoto N; Yamada S
J Control Release; 2009 Aug; 138(1):16-23. PubMed ID: 19376169
[TBL] [Abstract][Full Text] [Related]
12. Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid.
Wang XQ; Huang J; Dai JD; Zhang T; Lü WL; Zhang H; Zhang X; Wang JC; Zhang Q
Int J Pharm; 2006 Sep; 322(1-2):146-53. PubMed ID: 16787721
[TBL] [Abstract][Full Text] [Related]
13. The effect of particle size on bioavailability in cyclosporine preparations based on submicron dispersions.
Vrána A; Andrýsek T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):9-15. PubMed ID: 12426767
[TBL] [Abstract][Full Text] [Related]
14. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats.
Yang ZQ; Xu J; Pan P; Zhang XN
Pharmazie; 2009 Jan; 64(1):26-31. PubMed ID: 19216227
[TBL] [Abstract][Full Text] [Related]
15. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.
Kim ST; Jang DJ; Kim JH; Park JY; Lim JS; Lee SY; Lee KM; Lim SJ; Kim CK
Pharmazie; 2009 Aug; 64(8):510-4. PubMed ID: 19746839
[TBL] [Abstract][Full Text] [Related]
16. The role of particle size distribution on bioavailability of cyclosporine: novel drug delivery system.
Andrýsek T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):3-8. PubMed ID: 12426766
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
Müller RH; Runge S; Ravelli V; Mehnert W; Thünemann AF; Souto EB
Int J Pharm; 2006 Jul; 317(1):82-9. PubMed ID: 16580159
[TBL] [Abstract][Full Text] [Related]
18. [Preparation of cyclosporine A pH sensitive nanoparticles and oral pharmacokinetics in rats].
Dai JD; Wang XQ; Zhang T; Meng M; Zhang X; Lü WL; Zhang Q
Yao Xue Xue Bao; 2004 Dec; 39(12):1023-7. PubMed ID: 15813034
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A.
Dai J; Nagai T; Wang X; Zhang T; Meng M; Zhang Q
Int J Pharm; 2004 Aug; 280(1-2):229-40. PubMed ID: 15265562
[TBL] [Abstract][Full Text] [Related]
20. Effect of probucol on the oral bioavailability of cyclosporine A.
Sugimoto K; Sudoh T; Tsuruoka S; Yamamoto Y; Maezono S; Watanabe Y; Fujimura A
Eur J Pharm Sci; 2004 May; 22(1):71-7. PubMed ID: 15113585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
